Primary Treatment of Waldenstrom's Macroglobulinemia With Bortezomib (Velcade) and Rituximab (Rituxan) Followed by Autologous Stem Cell Collection

Trial Profile

Primary Treatment of Waldenstrom's Macroglobulinemia With Bortezomib (Velcade) and Rituximab (Rituxan) Followed by Autologous Stem Cell Collection

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Bortezomib (Primary) ; Cladribine; Cyclophosphamide; Cyclophosphamides; Dexamethasone; Doxorubicin; Rituximab; Valaciclovir; Vincristine
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 08 Dec 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017, according to ClinicalTrials.gov record.
    • 04 Dec 2014 Planned primary completion date changed from 1 Feb 2015 to 1 Feb 2016, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top